AstraZeneca PLC (NASDAQ:AZN) is one of the best immunotherapy stocks to buy according to hedge funds. AstraZeneca PLC (NASDAQ:AZN) received an update from Deutsche Bank on February 16, with the firm reiterating a Sell rating on the stock and setting a price target of £115. AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation In a separate development, AstraZeneca PLC (NASDAQ:AZN) announced on February 13 the full results from the positive Phase III KALOS and LOGOS trials, showing ...